Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma

Cancer. 1983 Jun 1;51(11):2035-40. doi: 10.1002/1097-0142(19830601)51:11<2035::aid-cncr2820511113>;2-8.


Renal function in 24 patients with disseminated nonseminomatous testicular carcinoma treated with combination chemotherapy including cis-platinum was examined prospectively. Renal function was monitored by several determinations of glomerular filtration rate (GFR), effective renal plasma flow (ERPF) and serum creatinine, and beta-2-microglobulin. A reduction in GFR and ERPF was found at the end of the induction chemotherapy and at six weeks thereafter. Median GFR and ERPF decreased both 23% (P less than 0.01). Serum creatinine and beta-2-microglobulin concentrations however did not rise. It is suggested that under the influence of chemotherapy with platinum the production of creatinine and beta-2-microglobulin is decreased rendering their serum levels unsuitable as parameters of renal function.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Agents / administration & dosage
  • Cisplatin / administration & dosage
  • Cisplatin / pharmacology*
  • Creatinine / blood
  • Drug Therapy, Combination
  • Glomerular Filtration Rate / drug effects
  • Humans
  • Kidney / drug effects*
  • Male
  • Prospective Studies
  • Renal Circulation / drug effects
  • Testicular Neoplasms / drug therapy*
  • beta 2-Microglobulin / analysis


  • Antineoplastic Agents
  • beta 2-Microglobulin
  • Creatinine
  • Cisplatin